Which of the following actions is typically NOT considered appropriate in response to an adverse event report? Response:

Question

Options

• AImmediate recall of all products potentially affected.
• BReporting the event to regulatory authorities within the required timeframe.
• CWaiting for multiple reports of a similar event before taking any action.
• DReviewing and updating product information to include the adverse event.

• A
  9% (2)
• B
  5% (1)
• C
  82% (18)
• D
  5% (1)

Explanation

Waiting for multiple reports before acting (C) violates the core principle of adverse event management: a single credible report can warrant immediate action. Regulatory frameworks like FDA and EMA require proactive, precautionary responses - not a "wait and see" approach - because delayed action can cause additional patient harm.

Why the distractors are wrong:

• A is appropriate - product recall is a legitimate and often required response when safety signals emerge.
• B is appropriate - timely reporting to regulators (e.g., within 15 days for serious unexpected events) is a legal obligation.
• D is appropriate - updating product labeling/package inserts to reflect new safety findings is standard pharmacovigilance practice.

Memory tip: Think of the phrase "One is enough to act" - in patient safety, the precautionary principle means you treat even a single serious adverse event report as a potential signal requiring investigation, not confirmation from a pattern.

No community discussion yet for this question.